Anders Jack sold $3.4M of RVMD
Anders Jack (Chief Financial Officer) sold 20,000 shares of Revolution Medicines, Inc. (RVMD) at an average of $168.33 ($167.34–$170.32, $3.37M total) across 4 trades on 2026-06-24 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale amount and execution window, with explicit confirmation of a pre-arranged 10b5-1 plan.
Market read
This provides incremental sentiment data (insider selling) but no new fundamental information to drive repricing.
What to watch
Traders may over-weight insider sales; the key missing context is whether there were concurrent buys by other insiders or any new RVMD-specific catalysts around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for Revolution Medicines, Inc. (RVMD).
Ticker impact
Revolution Medicines CFO Anders Jack sold about 20,000 shares in open-market trades totaling $3.37M under a 10b5-1 plan.
Limited near-term impact; any effect is likely sentiment-only and outweighed by broader fundamentals.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and it does not include new company guidance, trial results, or regulatory/contract developments.
Market effects
Minimal; insider-sale Form 4s typically do not reset biotech sector expectations without accompanying fundamental news.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations, so the market reaction should be muted.
Key entities
- issuerRevolution Medicines, Inc.
Biopharma company whose CFO insider sale is disclosed on Form 4.
- insiderAnders Jack
Chief Financial Officer who executed the reported open-market sales.
